A Prospective, Observational Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular Dystrophy

Study Summary

This is a prospective observational study conducted to evaluate safety, tolerability, and functional outcomes of patients with DMD newly initiating oral givinostat or having started therapy within 6 months as part of routine clinical care in the US. The study has a planned maximum duration of 5 years for the first enrolled patients, including a 24-month enrollment period and a minimum of 2 years of follow-up.

Interventions

No interventions listed.

Study Locations

Facility	City	State	Country
Ann and Robert H. Lurie Children's Hospital of Chicago	Chicago	Illinois	United States
University of Massachusetts Chan Medical School	Worcester	Massachusetts	United States

Official Trial Information

View on ClinicalTrials.gov